Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid J Chang

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Hypertension (Dallas, Tex. : 1979)|December 30, 2004
Are all COX-2 inhibitors created equal?Ingrid J Chang, Raymond C Harris
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 29, 2003
A 66-year-old woman with progressive renal insufficiency, nephrotic syndrome, and monoclonal proteinIngrid J Chang, Boonyarit Cheunsuchon, Frank J Miller, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 2, 2013
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trialJamie P Dwyer, Mohammed Sika, Gerald Schulman, et al.
Journal of the American Society of Nephrology : JASN|July 26, 2014
Ferric citrate controls phosphorus and delivers iron in patients on dialysisJulia B Lewis, Mohammed Sika, Mark J Koury, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Hypertension (Dallas, Tex. : 1979)|December 30, 2004
Are all COX-2 inhibitors created equal?Ingrid J Chang, Raymond C Harris
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 29, 2003
A 66-year-old woman with progressive renal insufficiency, nephrotic syndrome, and monoclonal proteinIngrid J Chang, Boonyarit Cheunsuchon, Frank J Miller, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 2, 2013
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trialJamie P Dwyer, Mohammed Sika, Gerald Schulman, et al.
Journal of the American Society of Nephrology : JASN|July 26, 2014
Ferric citrate controls phosphorus and delivers iron in patients on dialysisJulia B Lewis, Mohammed Sika, Mark J Koury, et al.
Pageof 1